AtaiBeckley is a clinical-stage biotech developing psychedelic-derived drug treatments for mental health disorders, primarily treatment-resistant depression (TRD) and anxiety. The company was formed in November 2025 through the combination of atai Life Sciences and Beckley Psytech, and is headquartered in New York. AtaiBeckley generates no revenue; it funds operations through equity financing and grants. The company has four pipeline programs. BPL-003 is an intranasal formulation of 5-MeO-DMT for TRD and is the most advanced asset, having completed a positive Phase 2b trial and received FDA End-of-Phase 2 feedback; two pivotal Phase 3 trials enrolling roughly 650 patients combined are planned to begin in Q2 2026. VLS-01 is a buccal film formulation of DMT for TRD currently in a Phase 2 trial, with topline data expected in the second half of 2026. EMP-01 is an oral formulation of R-MDMA for social anxiety disorder that met its Phase 2a primary endpoint of safety and tolerability. A fourth preclinical program targets novel non-hallucinogenic compounds for TRD and opioid use disorder, supported by up to $11.4M in NIH grant funding. A key design principle across AtaiBeckley's pipeline is short session duration — most treatments are designed to resolve within two hours — deliberately fitting within the in-clinic reimbursement model established by J&J's Spravato. AtaiBeckley's IP focuses on proprietary formulations and delivery mechanisms rather than the underlying molecules, with over 100 issued patents globally.